Small Pharma Inc. (CVE:DMT – Get Free Report)’s share price fell 6.3% during trading on Friday . The stock traded as low as C$0.15 and last traded at C$0.15. 1,890,765 shares traded hands during trading, an increase of 538% from the average session volume of 296,159 shares. The stock had previously closed at C$0.16.
Small Pharma Stock Performance
The company’s 50-day simple moving average is C$0.15 and its 200 day simple moving average is C$0.15. The company has a current ratio of 2.63, a quick ratio of 6.28 and a debt-to-equity ratio of 5.95. The stock has a market cap of C$50.37 million, a P/E ratio of -2.14 and a beta of 0.86.
About Small Pharma
Small Pharma Inc, a biotechnology company, focuses on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions. Its clinical program is based on N,N, dimethyltryptamine, a naturally occurring psychoactive molecule. The company's product includes SPL026, which is in clinical Phase IIa for the treatment of major depressive disorder; and SPL028, an injectable formulation of deuterated DMT, which is in Phase 1 clinical trial, as well as SPL801B, an oral dosage.
Featured Stories
- Five stocks we like better than Small Pharma
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- When to Sell a Stock for Profit or Loss
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for Small Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Small Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
